August 20, 2021 -- Ginkgo Bioworks reported higher revenue for the first half of 2021, with new cell programs and collaborations fueling the company's growth, according to an update by the company.
Ginkgo's total revenue was $88 million, up from $31 million in the same period in 2020, an increase of 180%. Revenue from the company's foundry business contributed $44 million, up from $31 million from the first half of 2020. Biosecurity revenue was $44 million, relative to an original full-year projection of $50 million.
Highlights for the period included the launch of 11 new cell programs and an increased estimate for total new programs from 23 to 30 by the end of 2021. Ginkgo also said that several cell programs were delivered to customers or are nearing completion and are expected to contribute downstream value in 2021.
Copyright © 2021 scienceboard.net